Primary liver cancer, hepatocellular carcinoma (HCC), is the fifth most common cancer and
the third leading cancer killer in the world. There is no effective therapeutic option for most
HCC patients. A new therapeutic strategy is essential. Granulin-epithelin precursor (GEP,
also called progranulin, acrogranin, or PC-derived growth factor) was identified as a
potential therapeutic target for HCC from our earlier genome-wide expression profiles. We
aimed to conduct a detailed investigation within vitroand animal experiments. We developed …